Vanguard Capital Management
FBLG icon

Vanguard Capital Management’s FibroBiologics FBLG Stock Holding History

Vanguard Capital Management’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3K Sell
27,769
-39,896
-59% -$46.3K ﹤0.01% 3995
2026
Q1 		$89.3K Buy
+67,665
New +$402K ﹤0.01% 3872

Other funds holding FBLG

CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
FEG
Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management's FBLG Position: Q2 2026 in Review

Vanguard Capital Management reduced its FibroBiologics (FBLG) stake by 59% in Q2 2026, selling an estimated $46.3K and leaving 27,769 shares worth $26.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3995.

Vanguard Capital Management first reported a position in FBLG in Q1 2026 and has held it in 2 quarters since. The position peaked at $89.3K in Q1 2026. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

  • Vanguard Capital Management held 27,769 shares of FibroBiologics worth $26.3K as of Q2 2026.
  • Vanguard Capital Management sold 39,896 FibroBiologics shares in Q2 2026, an estimated $46.3K.
  • FibroBiologics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3995 holding.
  • Vanguard Capital Management first reported a position in FibroBiologics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's FibroBiologics position peaked at $89.3K in Q1 2026.
  • 16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.